Introduction
Synthetic cannabinoids include various psychoactive chemicals that are sprayed onto plant material, which is then smoked or ingested to achieve a "high." These products are sold under a variety of names (e.g., synthetic marijuana, spice, K2, black mamba, and crazy clown) and are sold in retail outlets as herbal products and are often labeled not for human consumption. Law enforcement agencies regulate many of these substances; however, manufacturers may frequently change the formulation and mask their intended purpose to avoid detection and regulation.
On April 6, 2015, automated surveillance algorithms via surveillance through the National Poison Data System (NPDS), a web-based surveillance system of all calls to United States (US) poison centers (PCs), identified an increase in calls to PCs related to synthetic cannabinoid use. To identify risk factors and adverse health effects, CDC analyzed all calls to PCs about synthetic cannabinoid use from January to May, 2015.
Methods
We defined a synthetic cannabinoid call as any human exposure to a PC where use of a synthetic cannabinoid product was known or suggested during January to May 2015. We identified calls using NPDS and compared total and monthly call volumes during the study period to the same months in the previous year. Descriptive statistics for sex, age, most frequent signs and symptoms, medical outcome, and route of exposure were calculated. NPDS medical outcome designations utilized for this study included one of the following: 1) death, 2) major (signs or symptoms that are life-threatening or result in substantial residual disability or disfigurement), 3) moderate (signs and symptoms which are not likely to be life-threatening or result in severe disability), 4) minor (signs or symptoms that are minimally bothersome and generally resolve rapidly with no residual disability or disfigurement), or 5) not followed (the patient likely exhibited only minimal toxicity based on clinical judgment). We identified the most common drugs used when multiple substance use was reported. We compared demographic characteristics of calls reporting more severe medical outcomes (major effect and death) to calls reporting less severe outcomes (moderate effect, minor effect, no effect, not followed).
Results
During the 2015 study period, PCs reported 3,572 calls related to synthetic cannabinoid use, a 229% increase from the 1,085 calls during the same January-May period in 2014. Males were significantly more likely to have a severe outcome (88.6%) than a less severe outcome (80.1%) (p<0.001). Age group and severity were significantly associated with each other (p<0.001); persons aged 30-39 years and aged >40 years were significantly more likely than those aged 10-19 years to report a severe outcome (p = 0.001 and p<0.001, respectively).
Conclusions
Increased calls related to synthetic cannabinoid use likely related to availability of new variants suggest that synthetic cannabinoids pose an emerging public health threat. The increase in calls described here suggest a need for greater public health surveillance and awareness and targeted public health messaging.
